Head-to-head evidence
peginterferon beta-1a vs Rebif (interferon beta 1a)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
peginterferon beta-1a · Plegridy
Marketed by Biogen
NCT00906399 · Phase 3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).
Next expected readout: May 2027 · NCT03958877 (registry estimate)
Rebif (interferon beta 1a)
Marketed by Merck KGaA and partners
NCT00110396 · Phase 3 · completed
The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: peginterferon beta-1a's landscape · Rebif (interferon beta 1a)'s landscape